Glucagon-like receptor-1 agonists and impotence: A meta-analysis

Table 1 The effects of glucagon-like peptide receptors-1 agonists on erectile dysfunction

Ref.	Country	Age/years/GLP-1 agonists/control	BMI/GLP-1 agonists/control	Study type	Duration	GLP-1 type	Control	Score before	Score after	Number of patients/GLP-1 agonists/control
Defeudis et al[19]	Italy	64.1 ± 9.9 vs 62.3 ± 7.6	28.1 ± 3.6 vs 29.3 ± 5.6	Prospetive	48 months	GLP-1 agonists	Metformin	15.5 ± 5.7 vs 16.7 ± 4.7	-	20 vs 51
Giagull et al[20]	Italy	53.5 ± 4.4	34.2 ± 2.4	Retro.	12 months	Liraglutide	Cross-over	12 ± 2.2 vs 14.6 ± 1.7	14.6 ± 1.7 vs 19.9 ± 2	30 vs 16
Giagulli et al[21]	Italy	51.1 ± 2.9	33.5 ± 1.4	Retro.	12 months	Dulaglutide	Metformin	15.7 ± 1.7 vs 15.1 ± 1.1	18.0 ± 1.0 vs 19.1 ± 1.2	14 vs 14
Giagulli et al[21]	Italy	49.8 ± 2.9	34.0 ± 1.5	Retro	12 months	Liraglutide	Metformin	15.7 ± 1.7 vs 15.1 ± 1.1	15.1 ± 1.1 vs 18.7 ± 0.9	16 vs 16
La Vignera et al[22]	Italy	56.3 ± 4.7 vs 55.1 ± 5.2	35.3 ± 3.0 vs 34.6 ± 3.4	Pilot	8 weeks	Tirzepatide	Pilot	6.6 ± 1.5 vs 7.1 ± 1.25	8.8 ± 1.5 vs 7.3 ± 1.25	28 vs 30
Lengsfeld et al[23]	Switzerland	23.5 ± 4.15 vs 25 ± 3.25	24.1 ± 1.35 vs 23.2 ± 1.15	Trial	4 weeks	Dulaglutide	Placebo	9.8 ± 1 vs 10.4 ± 0.7	10.8 ± 2.6 vs 11 ± 1.9	12 vs 12
Lisco et al[24]	Italy	59 ± 4.5 vs 60 ± 3	34 ± 1.7 vs 33.7 ± 1.7	Retro.	12 months	Not specified	Metformin	15.3 ± 1.4 vs 15.7 ± 1.7	18.9 ± 1.2 vs 16.7 ± 1.5	63 vs 45

BMI: Body mass index; GLP-1 agonists: Glucagon-like peptide receptors-1 agonists.